Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 166 AL 180

Cholesterol and Alzheimer's disease: a still poorly understood correlation

Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA, Domenicotti C.

IUBMB Life. 2012 Dec;64(12):931-5. doi: 10.1002/iub.1091. Epub 2012 Nov 2.

Alzheimer disease in 2020

Holtzman DM, Mandelkow E, Selkoe DJ.

Cold Spring Harb Perspect Med. 2012 Nov 1;2(11):a011585. doi: 10.1101/cshperspect.a011585.

Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins

Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB.

Arch Med Res. 2012 Nov;43(8):699-704. doi: 10.1016/j.arcmed.2012.10.010. Epub 2012 Nov 3.

Deregulated Cdk5 activity is involved in inducing Alzheimer's disease

Shukla V, Skuntz S, Pant HC.

Arch Med Res. 2012 Nov;43(8):655-62. doi: 10.1016/j.arcmed.2012.10.015. Epub 2012 Nov 7.

Wnt signaling: role in Alzheimer disease and schizophrenia

Inestrosa NC, Montecinos-Oliva C, Fuenzalida M.

J Neuroimmune Pharmacol. 2012 Dec;7(4):788-807. doi: 10.1007/s11481-012-9417-5. Epub 2012 Nov 18.

Current therapeutic strategy in Alzheimer's disease

Singh S, Kushwah AS, Singh R, Farswan M, Kaur R.

Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1651-64.

Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation

Lindsley CW.

ACS Chem Neurosci. 2012 Nov 21;3(11):804-5. doi: 10.1021/cn300190f.

Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease

Fernández-Morales JC, Arranz-Tagarro JA, Calvo-Gallardo E, Maroto M, Padín JF, García AG.

ACS Chem Neurosci. 2012 Nov 21;3(11):873-83. doi: 10.1021/cn3001069. Epub 2012 Aug 29.

Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals

Swaminathan S, Huentelman MJ, Corneveaux JJ, Myers AJ, Faber KM, Foroud T, Mayeux R, Shen L, Kim S, Turk M, Hardy J, Reiman EM, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative and NIA-LOAD/NCRAD Family Study Group.

PLoS One. 2012;7(12):e50640. doi: 10.1371/journal.pone.0050640. Epub 2012 Dec 5.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease

Francis PT, Parsons CG, Jones RW.

Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124.

An overview on potential neuroprotective compounds for management of Alzheimer's disease

Sheikh IA, Ali R, Dar TA, Kamal MA.

CNS Neurol Disord Drug Targets. 2012 Dec;11(8):1006-11. doi: 10.2174/1871527311211080010.

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice

Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D, Silvestri E, Canzoniero LM, Sekler I, Pandolfi A, Sensi SL.

Cell Death Dis. 2012 Dec 20;3(12):e448. doi: 10.1038/cddis.2012.189.

[Tacrine and its derivatives in the therapy of Alzheimers disease]

Korábečný J, Spilovská K, Benek O, Musílek K, Soukup O, Kuča K.

Ceska Slov Farm. 2012 Oct;61(5):210-21.

Curcuminoids and resveratrol as anti-Alzheimer agents

Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY.

Taiwan J Obstet Gynecol. 2012 Dec;51(4):515-25. doi: 10.1016/j.tjog.2012.09.005.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias